Novo says diabetes drug IDegLira shows superior blood sugar control

COPENHAGEN Mon Dec 2, 2013 6:45pm EST

COPENHAGEN Dec 3 (Reuters) - Denmark's Novo Nordisk said on Tuesday that a phase 3 trial of its diabetes drug IDegLira showed better control of blood sugar levels than its own long-acting insulin Tresiba.

IDegLira is a combination of Tresiba and Victoza, Novo's glucagon-like peptide-1 (GLP-1) diabetes drug. GLP-1 drugs work by stimulating the release of insulin when blood sugar levels become too low.

Novo, the world's biggest insulin producer, said in a separate press release that its combination diabetes drug Ryzodeg showed improved glycaemic control, with lower rates of hypoglycaemia than biphasic insulin aspart 30.

Sales of diabetes drugs were worth $42.4 billion worldwide in 2012, according to healthcare information company IMS Health. France's Sanofi and U.S. company Eli Lilly are Novo's main competitors in the market.

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.